Psilocybin Safe, Effective for TRD: Phase 3 Data

Compass Pathways announced positive topline results from its Phase 3 COMP005 trial, indicating a single 25-mg dose of its synthetic psilocybin, COMP360, significantly reduced symptoms of treatment-resistant depression (TRD) at 6 weeks compared to placebo, meeting its primary endpoint. The trial reported no unexpected safety concerns, marking the first Phase 3 efficacy data for an investigational synthetic psilocybin. These results are significant for TRD patients and position COMP360 as a potential novel therapeutic, with the company planning FDA discussions and continuing further trial phases.

Analysis

Compass Pathways (CMPS) has announced a significant clinical milestone with positive topline results from its Phase 3 COMP005 trial for COMP360, a synthetic psilocybin formulation for treatment-resistant depression (TRD). The study successfully met its primary endpoint, demonstrating a statistically significant (P < .001) and clinically meaningful reduction in depression symptoms at 6 weeks compared to placebo, as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS). The reported mean treatment difference of -3.6 quantifies the drug's effect. Critically, the trial revealed no new or unexpected safety findings and no clinically meaningful imbalance in suicidal ideation, a key concern for psychiatric drug development. This achievement is particularly noteworthy as it represents the first Phase 3 efficacy data for an investigational synthetic psilocybin, positioning Compass at the forefront of the emerging psychedelic medicine sector. While the company plans to discuss these results with the FDA, further data from longer-term follow-ups and a second, larger Phase 3 trial (COMP006) are still pending, with the next major data readout not expected until the second half of 2026, indicating a protracted development and regulatory timeline.

Key Decisions for Investors

• The positive Phase 3 data represents a significant de-risking event for Compass Pathways' lead asset, COMP360, and strongly validates its potential in the high-unmet-need market for treatment-resistant depression.
• Investors should closely monitor upcoming catalysts, particularly the outcome of planned discussions with the US Food and Drug Administration, which will provide crucial clarity on the regulatory pathway and potential timeline for approval.
• While these 6-week results are highly encouraging, it is essential to factor in the extended investment horizon, as further pivotal data from ongoing trials, which will inform the complete efficacy and safety profile, is not expected until H2 2026.